To evaluate changes in M2BPGi levels in patients with HCV mono‐ and HCV/HIV co‐infection who received direct‐acting anti‐viral (DAA) therapy
Latest Information Update: 18 Oct 2020
At a glance
- Drugs Elbasvir/grazoprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
Most Recent Events
- 29 Aug 2020 Results (n=85) assessing dynamic changes of serum M2BPGi as a fibrosis marker of patients with HCV mono-infection and HCV/HIV co-infection receiving direct-acting anti-viral therapy, presented at The International Liver Congress 2020
- 06 Mar 2020 New trial record